In a report released on May 14, Stephen Willey from Stifel Nicolaus maintained a Hold rating on MEI Pharma (MEIP – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $3.11.
According to TipRanks, Willey is a 4-star analyst with an average return of 7.1% and a 41.28% success rate. Willey covers the Healthcare sector, focusing on stocks such as Geron, MacroGenics, and Zymeworks.
Currently, the analyst consensus on MEI Pharma is a Hold with an average price target of $6.00.
MEIP market cap is currently $21.05M and has a P/E ratio of 0.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MEI Pharma (MEIP) Company Description:
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
